Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.

British Journal of Cancer
Takuji OkusakaYuji Nimura

Abstract

A British randomised study of gemcitabine plus cisplatin (GC) combination showed promising results in biliary tract cancer (BTC) patients. In our study, we evaluated the efficacy and safety of this combination compared with gemcitabine alone (G) in Japanese BTC patients. Overall, 84 advanced BTC patients were randomised to either cisplatin 25 mg m(-2) plus gemcitabine 1000 mg m(-2) on days 1, 8 of a 21-day cycle (GC-arm), or single-agent gemcitabine 1000 mg m(-2) on days 1, 8 and 15 of a 28-day cycle (G-arm). Treatments were repeated for at least 12 weeks until disease progression or unacceptable toxicity occurred, up to a maximum of 48 weeks. A total of 83 patients were included in the analysis. For the GC and G-arms, respectively, the 1-year survival rate was 39.0 vs 31.0%, median survival time 11.2 vs 7.7 months, median progression-free survival time 5.8 vs 3.7 months and overall response rate 19.5 vs 11.9%. The most common grade 3 or 4 toxicities (GC-arm/G-arm) were neutropenia (56.1%/38.1%), thrombocytopenia (39.0%/7.1%), leukopenia (29.3%/19.0%), haemoglobin decrease (36.6%/16.7%) and gamma-GTP increase (29.3%/35.7%). Gemcitabine plus cisplatin combination therapy was found to be effective and well tolerated, suggesting t...Continue Reading

References

Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S ThongprasertS Moonprakan
Sep 6, 2005·Cancer Chemotherapy and Pharmacology·Takuji OkusakaToshio Tsuyuguchi
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William R JarnaginBhuvanesh Singh
May 27, 2006·Journal of Gastroenterology and Hepatology·Byung Kyu ParkSi Young Song
Dec 13, 2006·Critical Reviews in Oncology/hematology·Lara Maria PasettoSilvio Monfardini
Feb 1, 2007·Cancer Causes & Control : CCC·M T Goodman, Jennifer Yamamoto
Feb 28, 2007·British Journal of Cancer·F Eckel, R M Schmid
Mar 17, 2007·Cancer Chemotherapy and Pharmacology·Jeeyun LeeUNKNOWN Korean Cancer Study Group
Jun 15, 2007·World Journal of Gastroenterology : WJG·Chaiyut CharoentumSutthirak Munprakan
Jun 29, 2007·Digestive Diseases and Sciences·Jeffrey A MeyerhardtCharles S Fuchs
Aug 1, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G RandiC La Vecchia
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn D SeibBrent T Shoji
Sep 15, 2009·World Journal of Gastroenterology : WJG·Murad AljiffryMichele Molinari

❮ Previous
Next ❯

Citations

Apr 29, 2014·Hepatic Oncology·Jesper B Andersen, Snorri S Thorgeirsson
Mar 13, 2014·Journal of Translational Medicine·Atsushi ArugaMasakazu Yamamoto
Apr 24, 2014·Japanese Journal of Clinical Oncology·Hiroyuki TakahashiTatsuhiro Shibata
Dec 20, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J W ValleT Okusaka
Feb 1, 2014·Japanese Journal of Clinical Oncology·Hirokazu ShojiTakuji Okusaka
Jun 11, 2014·Medical Oncology·Jason Adhikaree, Srinivasan Madhusudan
Apr 29, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A LamarcaJ W Valle
May 26, 2011·World Journal of Clinical Oncology·Minoru TadaKazuhiko Koike
Jan 18, 2013·World Journal of Gastroenterology : WJG·Takashi SasakiKazuhiko Koike
Nov 11, 2010·Japanese Journal of Clinical Oncology·Amal HalimYaser Saleh
Jul 25, 2012·Japanese Journal of Clinical Oncology·Satoshi KobayashiSoichiro Morinaga
Sep 27, 2014·Expert Review of Gastroenterology & Hepatology·Takahiro TsuchikawaToshiaki Shichinohe
Dec 21, 2013·Expert Opinion on Emerging Drugs·Takuji OkusakaTatsuhiro Shibata
Oct 21, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BridgewaterJ W Valle
Nov 26, 2015·Japanese Journal of Clinical Oncology·Chandragouda DodagoudarNivedita Patnaik
Mar 31, 2016·Japanese Journal of Clinical Oncology·Junki MizusawaUNKNOWN Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group
May 13, 2015·Future Oncology·Bhawna SirohiShailesh V Shrikhande
Apr 4, 2015·Future Oncology·Bhawna SirohiShailesh V Shrikhande
May 21, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Joon Oh ParkHo Yeong Lim
Jun 4, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T GrenaderJ Bridgewater
Feb 5, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jieun LeeMyung Ah Lee
Apr 18, 2015·World Journal of Surgical Oncology·Takehiro NojiSatoshi Hirano
Apr 27, 2016·British Journal of Cancer·John BridgewaterHarpreet Wasan
Feb 24, 2017·Visceral Medicine·Martha M Kirstein, Arndt Vogel
Mar 11, 2017·Expert Opinion on Therapeutic Targets·Jennifer YangGregory B Lesinski
Mar 21, 2017·Expert Review of Gastroenterology & Hepatology·Amir A Rahnemai-AzarTimothy M Pawlik
Jun 9, 2016·Arquivos De Gastroenterologia·Rachel RiechelmannGabriel Prolla
Jan 22, 2017·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Byoung Hyuck KimYung-Jue Bang
Feb 15, 2017·Journal of Hepato-biliary-pancreatic Sciences·Anant RamaswamyShripad Banavali
Jan 22, 2017·American Journal of Surgery·Fumihiko MiuraTadahiro Takada
Jan 23, 2017·Current Gastroenterology Reports·Bryan DohertyWilliam C Palmer
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J W ValleUNKNOWN ESMO Guidelines Committee

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.